anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A total of 26 female participants aged between 18-65 years attended Oxford Brookes Centre for Nutrition and Health for two separate testing days. The study aimed to investigate the effects of energy matched ready meals (calorie-matched but differing quantities of protein and fat) on appetite and subsequent energy and macronutrient intake. The ready meals (Control = supermarket brand and Test = Slimming World) differed in energy density and macronutrient composition, with satiety responses investigated in the studies. The participants consumed a standard breakfast and four hours later consumed either a test ready meal (lasagne, higher energy density) or the control ready meal (lower energy density). Four hours after lunch participants food intake was measured during an ad libitum buffet tea. Additionally, satiety measurements were recorded using visual analogue scales throughout and participants completed a weighed food diary for the remainder of the test day.
The invention belongs to the field of pharmaceutical chemistry, and particularly relates to preparation of two emodin derivatives and evaluation of antitumor activity of the two emodin derivatives. The invention synthesizes the emodin derivative compound 1 and the emodin derivative compound 2 for the first time, and the structures of the emodin derivative compound 1 and the emodin derivative compound 2 are shown in the following figures. The antitumor activity of compound 1 and compound 2 was then evaluated using Hela cells. The results showed that the IC50 values of compound 1 and compound 2 against Hela cells were: 0.50.+ -. 0.16. Mu.M, 3.87.+ -. 0.71. Mu.M.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: substance for application as a medication, including solid mixed compound of metals of formula (I): MIIÇè1-aMIIIÇèaObAn-ÇèczH2O (I), where MII represents at least one bivalent metal, MIII represents Fe3+, An- represents at least one n-valent anion, z equals 2 or less, a = number of moles MIII /(number of moles MII + number of moles MIII), 2+a=2b+cn and cn<0.9a. Invention also relates to a method of obtaining said substance, which includes heating at temperature between 225C to 550C for 5 hours of compound, including structure of foliated double hydroxide. Invention also relates to application of said substance for obtaining a medication and pharmaceutical composition for binding phosphate and for prevention or treatment of hyperphosphatemia. ^ EFFECT: reducing the loss of bivalent metals in phosphate-binding substances. ^ 33 cl, 6 tbl, 2 ex
In the preoperative room patients will be asked to participate to the study and will be asked to answer the 4-item Jenkins-Sleep Questionaire.If they accept to participate, written informed consent will be taken from the patients. According to their answers to the questionaire , patients will be divided into two groups :those with or without insomnia.
A polymeric substance which contains acid amide groups in which the amide nitrogen atom carries an amino aryl substituent may be produced by reacting an aromatic diamine containing one or two primary or secondary amine groups with a polymer containing acid halide functions of the formula COX in which X denotes a halogen, the reaction being effected in the presence of an agent assisting the elimination of the hydrogen halide.  The characteristic grouping of the polymers of this invention is <FORM:0993181/C3/1> where R is a substituted or non-substituted arylene group, R1 and R11 being a hydrogen atom or a substituted or non-substituted alkyl group. Preferred polymers are those having the characteristic structure <FORM:0993181/C3/2> where R111 is a hydrogen atom or a methyl grouping. Preferably at least 10% of the acid amide groups are substituted as indicated and up to 100% may be so substituted.  The preferred starting material is polyacrylyl chloride and suitable aromatic diamines are nitro-paraphenylene diamine, 1-methyl-amino-2-nitro-4-amino benzene, 1-methyl-amino-2-nitro-4-(b -diethylaminoethyl - amino)benzene, 1 - nitro - 3 - amino - 4 - (b  - diethylaminoethyl - amino) - benzene and 1-4-diaminoanthraquinone. Solutions of the polymeric material are used as hair-colouring compositions.  The compositions may additionally contain other water-soluble polymers such as polyvinyl pyrrolidine or a vinyl acetate-crotonic acid copolymer.ALSO:Solutions of a polymeric substance which contains acid amide groups in which the amide nitrogen atom carries an amino aryl substituent are used as low colouring compositions.  The polymers are formed by reacting an aromatic diamine containing one or two primary or secondary amine groups with a polymer containing acid halide functions.  The characteristic grouping of the polymers of this invention is <FORM:0993181/D1-D2/1> where R1, R11 and R111 are hydrogen or lower allyl and R is a substituted or unsubstituted arylene group.  The hair-colouring compositions may consist simply of solutions of the coloured polymeric materials or may contain additionally other polymers such as polyvinylpyrolidine or a crotonic acid-vinyl acetate copolymer.
Participants are randomized to receive placebo by SQ injection. Participants are randomized at a 1:1:1:1 ratio across the 4 arms.
Provided are processes for preparing crystalline L-ornithine phenyl acetate salts. One method of preparation involves intermixing an L-ornithine salt, a benzoate salt and a solvent to form an intermediate solution; intermixing phenyl acetate with the solution; and isolating a composition comprising at least 70% crystalline L-ornithine phenyl acetate by weight. A second method involves increasing the pH value of a solution comprising an L-ornithine salt at least until an intermediate salt precipitates, wherein said intermediate salt is not an L-ornithine salt; isolating the intermediate salt from said solution; intermixing phenyl acetic acid with said solution; and isolating an L-ornithine phenyl acetate salt from said solution. A third method involves intermixing an L-ornithine salt, silver phenyl acetate and a solvent to form a solution, wherein the L-ornithine salt is a halide salt. Further provided are crystalline L-ornithine phenyl acetate salts which may, in some embodiments, be of Form I, II, III or V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.
Patients will receive 6 sessions of vocal hygiene training for initial comparison to patients in Arm 1. They will then receive 6 sessions of vocal exercise training and vocal hygiene training combined.
OBJECTIVE: The overlapping syndrome of anti-GFAP and anti-MOG antibodies is extremely rare. This retrospective study reports 8 adult cases of the GFAP-MOG overlapping syndrome.
METHODS: We reviewed the clinical characteristics of 8 adult patients with the GFAP-MOG overlapping syndrome from Jan 2019 and Sep 2023 at the Third Affiliated Hospital, Sun Yat-sen University. Moreover, we searched the literature and included all case reports with this overlapping syndrome since 2018 on PubMed.
RESULTS: The predominant clinical syndrome was meningoencephalomyelitis (5/8), followed by meningoencephalitis (2/8), and myelitis (1/8). Five patients had a flu-like prodromal symptom or diarrhea. No neoplasms were found in these patients. Regarding brain MRI, T2-weighted/fluid-attenuated inversion recovery hyperintensities were in 7 patients and leptomeningeal enhancement was in 4 patients. However, only one patient had periventricular radial linear enhancement. Besides, two patients had large space-occupying lesions. For spinal MRI, T2-hyperintensities were observed in 4 patients, in which 3 patients had longitudinally extensive lesions. All patients were treated with immunotherapy, the median follow-up period was 18 months (range, 3-36 months). Three patients presented relapses during the follow-up, but all cases recovered to mRS scores ≤ 2 at last follow-up. In addition, we also reviewed 14 cases (including 7 adults and 7 children) with this overlapping syndrome by literature review.
CONCLUSION: Our findings provide data to understand the clinical features and prognosis of the GFAP-MOG overlapping syndrome. Recognizing this overlapping syndrome will expand our knowledge, allowing for better management of these patients.
Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses.   
Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects.

The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. Naltrexone implants do not appear to be a hepatotoxin at the recommended doses.

Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of Naltrexone implants should be discontinued in the event of symptoms and/or signs of acute hepatitis.
ADHF syndromes comprise around one million of emergency admissions per year in the United States, and the number of cases tripled in the last three decades, currently representing the main cause of hospital admission in patients over the age of 65 years. A recent study showed that among patients with similar risk in the presentation of ADHF, those admitted and treated in the emergency (in attempt to get early discharge) have higher mortality rate than those treated by hospitalization. On the other hand, uncertainty about the clinical course can also result in prolonged and unnecessary hospitalizations, which burdens the health system and consumes resources. Thus, It is vital to carry out studies that bring a better understanding of the pathophysiology of ADHF and to determine new risk stratification tools in the emergency department. Echocardiography is the most widely used imaging method and has a key role in the diagnosis and management of patients with HF. However, some methodological limitations of conventional echocardiography cause low reproducibility and intra and inter-observer agreement for some parameters, reducing their prognostic ability. In recent years, new technologies have been incorporated into the method in an attempt to overcome these limitations. One of these new technologies is echocardiography with "speckle tracking". The method, by its nature, has a significant advantage over parameters derived from conventional echocardiography, because of its ultrasound beam angle-independence. However, there is a paucity of data on this new technology in patients with ADHF in literature and we have not found studies evaluating the prognostic value of this method in a prospective cohort of patients in this condition. This study aims to develop knowledge of this assessment tool for cardiac mechanics in emergency care, exploring its potential prognostic value in patients with ADHF, aiming to assist the cardiologist in identifying eligible patients for early and safe discharge, and to identify those patients for whom hospitalization and longer treatment are recommended.
Participants will receive the commercially available NJOY ACE e-cigarette, nicotine pods (2 of each available flavor, for a total of 4 pods), and tailored instructions to switch. Participants will use the ACE ad libitum for 14 days, reporting their cigarette use, e-cigarette use, mood, and nicotine crazing every day via text message surveys.
Vascular access for hemodialysis is the lifeline for patients with end-stage renal disease (ESRD); therefore, maintenance of the vascular access is of the utmost importance. The dialysis circuit can be complicated by stenosis or thrombosis. In particular, central venous stenosis is frequently encountered in the vascular access of patients with ESRD, and this complication may require endovascular management. Conventional catheter-based venography may be inadequate for identifying dynamic forms of extrinsic compression and intravascular webs associated with these lesions. For these types of access complications, balloon angioplasty remains the first-line intervention, with stenting reserved for selected scenarios. Accurate assessment of the venous configuration is therefore important to ensure an adequate treatment response. Intravascular ultrasound (IVUS) has been shown to be beneficial in lower extremity venous interventions. The use of IVUS in dialysis access interventions is currently limited but may be indicated in selected challenging clinical situations. In this article, we discuss the potential uses of IVUS in the ESRD population based on our institutional experience and on the current literature.
Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
The ultimate goal of this application is to determine the cause(s) of type 2 diabetes mellitus. The role of the liver in the evolution of type 2 diabetes has not been as extensively studied as that of muscle. This has been, in part, due to the inherent difficulty of measuring hepatic insulin action in humans under physiologic conditions. Plasma free fatty acids (FFA) can cause insulin resistance in non-diabetic humans and are commonly elevated in people with type 2 diabetes. We will re-examine the mechanism(s) by which elevated FFA cause hepatic insulin resistance in non-diabetic humans, will determine whether elevated FFA alter insulin induced suppression of endogenous glucose production (EGP) in diabetic humans and if so, whether this is due to changes in glycogenolysis and/or gluconeogenesis. We will also seek to determine whether treatment with a pioglitazone (a thiazolidinedione) blunts or prevents FFA induced hepatic (and extrahepatic) insulin resistance in people with type 2 diabetes and whether the effects of FFA on insulin action are influenced by gender. We will examine if use of thiazolidinediones reduces cortisol production by changing the overall activity of 11 beta hydroxysteroid dehydrogenase type 1. We will also investigate whether use of thiazolidinediones alters objectively measured breathing or sleepiness in people with type 2 diabetes.
PURPOSE: A pharmaceutical composition containing a composite of non-steroidal anti-inflammatory agent and colchicoside derivative is provided to reduce impurities and to ensure stable composite. CONSTITUTION: A pharmaceutical composition contains non-steroidal anti-inflammatory agent and colchicoside derivative. The active ingredients of the composition are release state or salt form. The pharmaceutical composition is administered by oral path. The composition is used in the form of solid or film coating tablet. A pharmaceutical composition of solid form contains 100mg of ketoprofen and 8mg of thiocolchicoside.
BACKGROUND: Cardiac arrest after coronary artery bypass grafting (CABG) is a serious complication with low survival rate. The prognosis of patients with cardiac arrest in the general ward is worse than that in the intensive care unit (ICU) because of the delayed and poor rescue conditions.
METHODS: This retrospective study included patients who experienced cardiac arrest after CABG surgery between January 2010 and December 2019 at the Fuwai Hospital. Differences in cardiac arrest between the ICU and the general ward were compared. The patients were divided into shockable and non-shockable rhythm groups, and the differences between the two groups were compared. Finally, we proposed a management protocol for cardiac arrest in the general ward.
RESULTS: We retrospectively analyzed 41,450 patients who underwent CABG only, of whom 231 (0.56%) experienced cardiac arrest post-surgery in the ICU (185/231) or in the general ward (46/231). The rescue success rate and 30-day survival rate of the patients with cardiac arrest in the general ward were 76.1% (35/46) and 58.7% (27/46), respectively. The incidence of the different arrhythmia types of cardiac arrest in the general ward compared with that in the ICU was different (P = 0.010). The 30-day survival rate of the non-shockable rhythm group was 31.8% (7/22), which was worse than that of the shockable rhythm group (83.3% [20/24]; P = 0.001). Kaplan-Meier survival analysis showed that the prognosis of the non-shockable group was poor (P < 0.001).
CONCLUSIONS: The incidence of cardiac arrest after CABG was low. The prognosis of patients in the general ward was worse than that of those in the ICU. The proportion of non-shockable rhythm type cardiac arrest was higher in the general ward than in the ICU, and patients in this group had a worse early prognosis.
BACKGROUND: Postoperative atrial fibrillation (POAF) constitutes a significant complication following coronary artery bypass graft surgery (CABG), potentially linked to epicardial adipose tissue (EAT). This investigation seeks to elucidate the association between POAF and EAT at the genetic level.
METHODS: EAT and clinical data from patients undergoing CABG were systematically acquired, adhering to established inclusion and exclusion criteria. Patients were categorized into POAF and Non-POAF groups based on the presence or absence of POAF. High-throughput sequencing data of EAT were subjected to differential expression analysis and gene function assessment. A random selection of long noncoding RNAs (lncRNAs) underwent quantitative real-time polymerase chain reaction (qRT-PCR) for validation of the high-throughput sequencing findings. Coexpression analysis was employed to elucidate the interactions between lncRNAs and messenger RNAs (mRNAs).
RESULTS: RNA sequencing yielded a total of 69,685 transcripts (37,740 coding and 31,945 noncoding sequences), representing 16,920 genes. Within this dataset, 38 mRNAs and 12 lncRNAs exhibited differential expression between the POAF and Non-POAF groups (P < 0.05, fold change > 1.5). The qRT-PCR results for lncRNAs corroborated the sequencing findings (P < 0.01). Functional enrichment analysis of genes and the coexpression network indicated that these differentially expressed RNAs were primarily implicated in processes such as cell growth, differentiation, signal transduction, as well as influencing tissue fibrosis and ion transmembrane transport.
CONCLUSIONS: This study unveils a potential association between myocardial fibrosis and ion channels co-regulated by mRNAs and lncRNAs, closely linked to the emergence of new-onset POAF, after accounting for clinical risk factors. This discovery holds promise for further advances in clinical and fundamental research.
PROBLEM TO BE SOLVED: To obtain the subject new compound capable of giving improved glass which is easily mixable with an aqueous polyacrylic acid solution, has high fluoride ion releasing ability and can afford cement with improved diameter tensile strength and fracture toughness. SOLUTION: This new compound is represented by formula I (R1 to R4 are each H, CH3, COOH or CH2COOH; R5 and R6 are each a bivalent alkylene; R7 is an alkyl; T1 and T2 are each H or an alkyl; w is 0-12; x, y and z are each >=1), being obtained, for example, by reaction between an active hydrogen group-contg. ethylene-based unsaturated compound and an electrophilic group- bearing alkoxysilane; wherein the ethylene-based unsaturated compound is e.g. (meth)acrylic acid, maleic acid, itaconic acid; the alkoxysilane is pref. an isocyanato-functional alkoxysilane, specifically, e.g. isocyanatoethyltrimethoxysilane, isocyanatopropyltriethoxysilane.
Chlordiazepoxide Hydrochloride Capsules, USP, the original Chlordiazepoxide Hydrochloride and prototype for the benzodiazepine compounds, was synthesized and developed at Hoffmann-La Roche Inc. It is a versatile therapeutic agent of proven value for the relief of anxiety. Chlordiazepoxide Hydrochloride Capsule is among the safer of the effective psychopharmacologic compounds available, as demonstrated by extensive clinical evidence.

Chlordiazepoxide Hydrochloride is available as capsules containing 5 mg, 10 mg or 25 mg chlordiazepoxide hydrochloride. Each capsule also contains corn starch, lactose monohydrate and talc. Gelatin capsule shells may contain methyl and propyl parabens, Titanium Dioxide, Gelatin and potassium sorbate, with the following dye systems: 5-mg capsules - FD&C Yellow No. 6 plus D&C Yellow No. 10 and FD&C Green No. 3. 10-mg capsules - D&C Yellow No. 10, FD&C Blue No. 1, FD&C Green No. 3, FD&C Yellow No. 6 plus FD&C Red No. 40. 25-mg capsules - D&C Yellow No. 10 and FD&C Green No. 3.

Chlordiazepoxide hydrochloride is 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine 4-oxide hydrochloride. A white to practically white crystalline substance, it is soluble in water. It is unstable in solution and the powder must be protected from light. The molecular weight is 336.22. The structural formula of chlordiazepoxide hydrochloride is as follows:
Several studies reported the relationship between plasma phytosterol concentrations and parenteral nutrition-associated cholestasis (PNAC). Information on plasma phytosterols half-lives in very-low-birth-weight (VLBW) preterm infants on lipid parenteral nutrition (PN) are lacking. In a prospective cohort study, plasma phytosterols (campesterol, stigmasterol and sitosterol) of VLBW preterm infants on routine PN will be measured by gas chromatography-mass spectrometry (GC-MS) during PN administration and after only lipid stopping. Plasma phytosterols half-lives will be calculated from the monoexponential decay curves. Blood samples will be weekly collected from 1st to 7th week of life during routine metabolic tolerance analysis or gas-analysis in order to avoid burden of additional phlebotomy. Samples will be collected in ethylenediaminetetraacetic acid-tubes and immediately centrifugated. Plasma will be stored in pyrogallol added-tubes at -20°C until analysis. Saponification reaction will be done using 5-alpha-cholestane as internal standard.
Before emergence from anesthesia, the patient will be kept supine and oropharyngeal secretions will be suctioned. Anesthetic gas or IV agents will be stopped. Oxygen concentration will be inscreased to 100% with a fresh gas flow ≥10 L/min. The ventilator will be halted, APL valve opened to atmosphere, and the patient manually ventilated with the reservoir bag until spontaneous breathing resumes, followed by manual assistance as deemed necessary by the anesthesiologist.
In this Phase 3 portion, the study team will select appropriate measures, train staff and build capacity in measure implementation, and finalize the intervention for delivery by healthcare workers. Finally, in a training/proof-of-concept exercise, the healthcare workers will implement the adapted CAE-L in a high-risk sample of Tanzanians with CPD (individuals with schizophrenia or schizoaffective disorder who have had recent medication adherence problems). Taken together, the proposed project has substantial public health importance. It will provide the prerequisite materials, training and infrastructure needed for a prospective trial in reducing CPD burden and improving brain health in Tanzania and other countries in Sub-Saharan Africa.

The focus of this project is on feasibility, patient acceptability, and research capacity-building. Therefore a specific hypothesis is not being tested. The investigators will assess descriptive statistics and change from baseline in the primary and secondary measures using standard pre-post techniques.
In phase I, up 50 AD patients will be recruited and screened until we obtain 6 AD subjects. All potential subjects recruit will be pre-screened for initial inclusion/exclusion criteria via examination of standard of care (SOC) medical history, labs, imaging, and cognitive assessment. Recruited subjects will be scheduled for Study Visit #1 (@TRI) and will be further screened with protocol cognitive assessments, depression screening, assessment of daily activities, and labs. During Study Visit #2, these subjects will undergo structural imaging with high resolution magnetic resonance imaging (@ TRI) without contrast (MRI), to rule out other causes of cognitive decline.